

RSS: OB/GYN Grand Rounds 2025

Session Date: May 30, 2025 ● 8:00 AM – 9:00 AM

Title: *OB/GYN Grand Rounds 2025 - 5/30/25 - Anticoagulation issues in women's health: An update for 2025; Presented by Deborah Ornstein, MD*

Session Speaker:

Deborah L Ornstein, MD
Medical Director, Hemophilia and Thrombosis Center
Dartmouth Hitchcock Medical Center

Ilana Cass, MD
VP Svc Ln & Dept Chair-Ob/Gyn
Dartmouth Hitchcock Medical Center

Accreditation:

In support of improving patient care, Dartmouth Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Medical Association (AMA)

Dartmouth Health designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: All other learners may claim CME-designated participation credit. Consult your professional licensing board regarding the applicability and acceptance of CME-designated participation credit for programs certified for credit by organizations accredited by Joint Accreditation for Interprofessional Education.

Learning Objectives:

At the conclusion of this learning activity, participants will be able to:

- 1 Understand the principles of anticoagulation selection for women with venous thromboembolism
- 2 Review options for management of heavy menses in newly and chronically anticoagulated women
- 3 Gain awareness of updated recommendations for anticoagulant treatment of venous thromboembolism in women with cancer

Dartmouth Health adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including planners, faculty, authors, or others are required to disclose all financial relationships with ineligible companies[^]. All relevant financial relationships have been mitigated prior to the commencement of the activity.

[^]*Ineligible Company is any entity whose primary business purpose is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.*

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Tina C Foster, MD	Other Planning Committee Member	
Deborah L Ornstein, MD	Faculty	Nothing to disclose - 12/26/2024
Rebecca H Evans, MD	Other Planning Committee Member	Nothing to disclose - 09/19/2024
Ilana Cass, MD	Faculty	Nothing to disclose - 09/30/2024
Robert N Blatman, MD	Course Director	Nothing to disclose - 11/14/2024

Mobile Text-In Code for this Session Only

<Code>

Code Expires in 48 Hours

Text Requests for Credit to this Number:
(833-884-3375)

Need help?

clpd.support@hitchcock.org

Create New Account

dh.cloud-cme.com